Search Results - chemotherapy%2fchemotherapy

3 Results

Sort By:

Low Dose Adjuvant Epigenetic Modifiers Inhibit Cancer Lung Metastases through Disruption of the Myeloid Environment in Pre-metastatic Niches

Unmet NeedCancer recurrence, even following complete surgical resection, remains a large unmet clinical problem. In non-small cell lung cancer (NSCLC) patients, recurrence following surgery remains 30-70%, and the five-year survival rate remains 23% with over 140,000 deaths occurring each year. Recurrence post-surgery can be driven by a number of factors,...

Published: 6/28/2024 | Inventor(s): Malcolm Brock, Zhihao Lu

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules

Broad Spectrum Chemoprotective Activities of Exemstane Against Cancer and Other Chronic Diseases: Synergism with Sulforaphane

Estrogens control the growth and development of the majority of breast cancers, the most prevalent malignancies of women in the developed world. Exemestane, a synthetic steroid commonly used clinically to prevent, delay progression of, and treat breast cancer, was designed to inhibit estrogen biosynthesis by aromatase. We have made the unexpected observation...

Published: 6/27/2024 | Inventor(s): Hua Liu, Paul Talalay

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Natural compounds, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Compositions and Methods for Treating Solid Tumors

UNMET NEEDCancers are now recognized as being driven by widespread changes in the epigenome including changes in DNA methylation and chromatin packaging. Changes in DNA methylation include global loss of methylation and focal gain of methylation at promoter regions of tumor suppressor genes leading to transcriptional silencing. DNA methylation, the...

Published: 6/27/2024 | Inventor(s): Cynthia Zahnow, Stephen Baylin, Michael Topper, Meredith Stone

Keywords(s): Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type